Novo Nordisk Licenses Nanexa Drug-Delivery Tech in $1.3 Billion Deal for Monthly Obesity Shots

On September 24, 2026, Novo Nordisk executed a €1.165 billion ($1.3 billion) global licensing and collaboration agreement with Swedish drug-delivery startup Nanexa AB, securing exclusive rights to a technology designed to stretch the dosing window of injectable obesity medications from weekly to monthly. The transaction includes an upfront payment, development and sales milestones, and tiered royalties on future product sales, signaling a major capital allocation toward next-generation formulations of the Danish pharmaceutical giant's GLP-1 portfolio.[1][2][5]

The core asset in the transaction is Nanexa's PharmaShell system, a proprietary atomic layer deposition technology that coats drug particles with an ultra-thin inorganic shell. This coating regulates the release rate of the active pharmaceutical ingredient once injected under the skin, allowing a single dose to dissolve slowly over 30 days rather than peaking and clearing within a week.[1][4]

For Novo Nordisk, extending the half-life of its blockbuster semaglutide franchise addresses the most significant friction point in the current treatment paradigm: patient fatigue. Clinical data indicates that adherence to weekly injectable regimens drops sharply after the first six months, threatening long-term revenue retention in a global obesity drug market projected to exceed $100 billion by the end of the decade.[2][3]

Under the terms of the agreement, Novo Nordisk assumes full responsibility for the clinical development, manufacturing, and commercialization of any product utilizing the PharmaShell technology. Nanexa will provide preclinical support and initial material supply, transitioning from a research-stage partner to a royalty-collecting licensor if the monthly formulations clear regulatory hurdles.[1][5]

The $1.3 billion commitment arrives as the competitive moat around first-generation GLP-1 therapies narrows. Rival Eli Lilly continues to capture market share with its dual-agonist Zepbound, while a pipeline of oral weight-loss pills and alternative injectables from Amgen, Roche, and Viking Therapeutics threatens to commoditize the weekly injection model.[3][4]

By locking up Nanexa's delivery platform, Novo Nordisk is shifting the competitive frontier from the underlying molecule to the patient experience. A once-a-month injection schedule effectively neutralizes the convenience argument for daily oral pills, which often require strict fasting windows and carry distinct gastrointestinal side effect profiles.[2][4]

For Uppsala-based Nanexa, the transaction represents a transformative validation of its atomic layer deposition approach, which was originally adapted from the semiconductor industry. The upfront capital injection provides the startup with a multi-year cash runway to advance its own internal pipeline of long-acting oncology and hematology treatments, independent of the Novo Nordisk partnership.[1][5]

The collaboration now moves into the preclinical optimization phase, where Novo Nordisk researchers will attempt to formulate semaglutide or next-generation incretin molecules with the PharmaShell coating. The initial corporate disclosures did not contain direct executive quotations regarding the specific timeline for human trials, but standard development cycles suggest the first human trials for a monthly Wegovy successor could initiate within 18 to 24 months.[1][2]